Showing results (101-110 of 108) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Biomolecules|October 27, 2022
Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide EfficacyTomohiro Hosoya, Masamichi Takahashi, Calvin Davey, et al.Japanese Journal of Clinical Oncology|December 11, 2024
Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)-mutant astrocytoma may indicate radiation necrosisYukie Ozeki, Mai Honda-Kitahara, Shunsuke Yanagisawa, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2025
Chromosome 15q15 Deletion Drives Brain Metastasis in NSCLCJun Miyakoshi, Kouya Shiraishi, Akifumi Mochizuki, et al.Cancers|May 28, 2022
Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse GliomasTakaki Omura, Masamichi Takahashi, Makoto Ohno, et al.JNCI Cancer Spectrum|November 25, 2022
Prediction of tissue-of-origin of early stage cancers using serum miRNomesJuntaro Matsuzaki, Ken Kato, Kenta Oono, et al.Japanese Journal of Clinical Oncology|September 3, 2024
Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study groupKazuya Motomura, Keita Sasaki, Narushi Sugii, et al.Acta Neuropathologica Communications|August 10, 2016
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomasHideyuki Arita, Kai Yamasaki, Yuko Matsushita, et al.Acta Neuropathologica Communications|November 24, 2020
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutationsHideyuki Arita, Yuko Matsushita, Ryunosuke Machida, et al.Pageof 11